Cargando…

Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster

The novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented....

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Zhenye, Li, Xueqi, Gao, Yang, Wang, Lichun, Fan, Shengtao, Xu, Xingli, Jiang, Guorun, Cui, Pingfang, Li, Dandan, Liao, Yun, Yu, Li, Zhao, Heng, Zhang, Ying, Li, Qihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781188/
https://www.ncbi.nlm.nih.gov/pubmed/36560406
http://dx.doi.org/10.3390/vaccines10121996
_version_ 1784857012684718080
author Niu, Zhenye
Li, Xueqi
Gao, Yang
Wang, Lichun
Fan, Shengtao
Xu, Xingli
Jiang, Guorun
Cui, Pingfang
Li, Dandan
Liao, Yun
Yu, Li
Zhao, Heng
Zhang, Ying
Li, Qihan
author_facet Niu, Zhenye
Li, Xueqi
Gao, Yang
Wang, Lichun
Fan, Shengtao
Xu, Xingli
Jiang, Guorun
Cui, Pingfang
Li, Dandan
Liao, Yun
Yu, Li
Zhao, Heng
Zhang, Ying
Li, Qihan
author_sort Niu, Zhenye
collection PubMed
description The novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented. Whether multiple antigen matches are necessary to induce a better immune response remains unclear. To address this question, this study tested the immunogenicity and protective effects of a SARS-CoV-2 recombinant S and N peptide vaccine in the Syrian golden hamster model. This experiment was based on two immunization methods: intradermal and intramuscular administration. Immunized hamsters were challenged with live SARS-CoV-2 14 days after booster immunization. Clinical symptoms were observed daily, and the antibody titer and viral load in each tissue were detected. The results showed that immunization of golden hamsters with the SARS-CoV-2 structural protein S alone or in combination with the N protein through different routes induced antibody responses, whereas immunization with the N protein alone did not. However, although the immunized hamsters exhibited partial alleviation of clinical symptoms when challenged with the virus, neither vaccine effectively inhibited the proliferation and replication of the challenging virus. In addition, the pathological damage in the immunized hamsters was similar to that in the control hamsters. Interestingly, the neutralizing antibody levels of all groups including immunized and nonimmunized animals increased significantly after viral challenge. In conclusion, the immune response induced by the experimental S and N polypeptide vaccines had no significant ability to prevent viral infection and pathogenicity in golden hamsters.
format Online
Article
Text
id pubmed-9781188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97811882022-12-24 Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster Niu, Zhenye Li, Xueqi Gao, Yang Wang, Lichun Fan, Shengtao Xu, Xingli Jiang, Guorun Cui, Pingfang Li, Dandan Liao, Yun Yu, Li Zhao, Heng Zhang, Ying Li, Qihan Vaccines (Basel) Article The novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented. Whether multiple antigen matches are necessary to induce a better immune response remains unclear. To address this question, this study tested the immunogenicity and protective effects of a SARS-CoV-2 recombinant S and N peptide vaccine in the Syrian golden hamster model. This experiment was based on two immunization methods: intradermal and intramuscular administration. Immunized hamsters were challenged with live SARS-CoV-2 14 days after booster immunization. Clinical symptoms were observed daily, and the antibody titer and viral load in each tissue were detected. The results showed that immunization of golden hamsters with the SARS-CoV-2 structural protein S alone or in combination with the N protein through different routes induced antibody responses, whereas immunization with the N protein alone did not. However, although the immunized hamsters exhibited partial alleviation of clinical symptoms when challenged with the virus, neither vaccine effectively inhibited the proliferation and replication of the challenging virus. In addition, the pathological damage in the immunized hamsters was similar to that in the control hamsters. Interestingly, the neutralizing antibody levels of all groups including immunized and nonimmunized animals increased significantly after viral challenge. In conclusion, the immune response induced by the experimental S and N polypeptide vaccines had no significant ability to prevent viral infection and pathogenicity in golden hamsters. MDPI 2022-11-24 /pmc/articles/PMC9781188/ /pubmed/36560406 http://dx.doi.org/10.3390/vaccines10121996 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Niu, Zhenye
Li, Xueqi
Gao, Yang
Wang, Lichun
Fan, Shengtao
Xu, Xingli
Jiang, Guorun
Cui, Pingfang
Li, Dandan
Liao, Yun
Yu, Li
Zhao, Heng
Zhang, Ying
Li, Qihan
Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title_full Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title_fullStr Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title_full_unstemmed Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title_short Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
title_sort evaluation of immunogenicity and clinical protection of sars-cov-2 s1 and n antigens in syrian golden hamster
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781188/
https://www.ncbi.nlm.nih.gov/pubmed/36560406
http://dx.doi.org/10.3390/vaccines10121996
work_keys_str_mv AT niuzhenye evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT lixueqi evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT gaoyang evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT wanglichun evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT fanshengtao evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT xuxingli evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT jiangguorun evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT cuipingfang evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT lidandan evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT liaoyun evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT yuli evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT zhaoheng evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT zhangying evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster
AT liqihan evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster